IRIS
PERUCCA, EMILIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.377
AS - Asia 10.711
EU - Europa 8.270
SA - Sud America 1.305
Continente sconosciuto - Info sul continente non disponibili 415
AF - Africa 351
OC - Oceania 29
Totale 40.458
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.666
CN - Cina 5.268
SG - Singapore 2.365
IE - Irlanda 1.780
UA - Ucraina 1.389
HK - Hong Kong 1.138
BR - Brasile 970
DE - Germania 879
RU - Federazione Russa 816
IT - Italia 809
VN - Vietnam 773
FI - Finlandia 619
FR - Francia 594
GB - Regno Unito 500
SE - Svezia 461
CA - Canada 304
IN - India 233
BD - Bangladesh 195
ZA - Sudafrica 148
AR - Argentina 99
JP - Giappone 93
IQ - Iraq 89
MX - Messico 81
PL - Polonia 77
TR - Turchia 74
NL - Olanda 71
ID - Indonesia 65
PK - Pakistan 62
CO - Colombia 58
ES - Italia 45
NI - Nicaragua 45
VE - Venezuela 45
CR - Costa Rica 44
EC - Ecuador 42
UZ - Uzbekistan 42
SA - Arabia Saudita 40
IL - Israele 38
MY - Malesia 38
SV - El Salvador 37
BE - Belgio 36
TT - Trinidad e Tobago 36
PH - Filippine 35
KE - Kenya 34
CL - Cile 30
AT - Austria 29
EG - Egitto 29
GT - Guatemala 29
HN - Honduras 29
PR - Porto Rico 28
JM - Giamaica 27
TN - Tunisia 26
CW - ???statistics.table.value.countryCode.CW??? 25
AU - Australia 23
MA - Marocco 23
AE - Emirati Arabi Uniti 22
LT - Lituania 21
PE - Perù 20
PY - Paraguay 18
GP - Guadalupe 17
CZ - Repubblica Ceca 16
IR - Iran 16
EE - Estonia 14
MU - Mauritius 14
DZ - Algeria 13
JO - Giordania 13
KR - Corea 13
SC - Seychelles 13
AZ - Azerbaigian 12
SI - Slovenia 12
BG - Bulgaria 11
ET - Etiopia 10
SK - Slovacchia (Repubblica Slovacca) 10
TH - Thailandia 10
EU - Europa 9
NP - Nepal 9
PS - Palestinian Territory 9
RO - Romania 9
UY - Uruguay 9
CH - Svizzera 8
DO - Repubblica Dominicana 8
KZ - Kazakistan 8
PA - Panama 8
SN - Senegal 8
BO - Bolivia 7
GR - Grecia 7
TW - Taiwan 7
AL - Albania 6
BB - Barbados 6
BY - Bielorussia 6
KG - Kirghizistan 6
AO - Angola 5
DK - Danimarca 5
HR - Croazia 5
IS - Islanda 5
LK - Sri Lanka 5
MD - Moldavia 5
NO - Norvegia 5
RS - Serbia 5
AM - Armenia 4
LB - Libano 4
Totale 39.984
Salva come PNG Salva come JPEG
Città #
Chandler 1.862
Dublin 1.777
Jacksonville 1.673
San Jose 1.619
Ashburn 1.408
Nanjing 1.224
Singapore 1.211
Dallas 1.197
Hong Kong 1.111
Council Bluffs 1.042
Boardman 618
Beijing 576
Nanchang 472
Princeton 449
Los Angeles 438
Wilmington 419
Lawrence 417
Lauterbourg 371
Shenyang 360
Changsha 354
Hebei 347
Ho Chi Minh City 281
Jiaxing 279
Medford 271
Tianjin 219
New York 206
Hangzhou 198
Buffalo 196
Hanoi 188
Santa Clara 185
Ann Arbor 176
Redondo Beach 164
Helsinki 160
Milan 145
Woodbridge 128
Johannesburg 120
Moscow 114
Shanghai 106
Houston 104
Chicago 97
Fairfield 92
San Francisco 90
São Paulo 90
Saint Petersburg 85
North Bergen 84
Toronto 83
Orem 82
Verona 78
Atlanta 77
Tokyo 77
Norwalk 74
Brooklyn 70
Munich 67
Seattle 64
The Dalles 64
Columbus 56
Rome 56
Frankfurt am Main 55
Warsaw 55
Cambridge 53
Denver 53
Montreal 51
Phoenix 45
Des Moines 44
Chennai 43
Managua 42
Da Nang 38
Guangzhou 38
London 38
Baghdad 37
Naples 36
Tashkent 36
Zhengzhou 36
Charlotte 35
San Salvador 35
San José 34
Brussels 33
Washington 33
Kunming 32
Nuremberg 30
Pune 30
Pavia 29
Falls Church 28
Turku 28
Boston 27
Jinan 27
Dhaka 26
Nairobi 26
Falkenstein 25
Haiphong 25
Rio de Janeiro 25
Willemstad 25
Mexico City 24
Amsterdam 23
Dearborn 23
Guatemala City 23
Curitiba 22
Las Vegas 22
Manchester 21
Newark 21
Totale 25.003
Salva come PNG Salva come JPEG
Nome #
ILAE Official Report: A practical clinical definition of epilepsy 482
A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. 388
Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. 313
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. 260
ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology 211
Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and puerperium. 197
Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbamazepine in healthy women 190
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry 184
A simple and rapid HPLC-UV method for the determination of retigabine in human plasma 178
Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. 176
A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma 175
A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. 171
A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. 170
A multiparametric investigation of daytime sleepiness and psychomotor functions in epileptic patients treated with phenobarbital and sodium valproate: a comparative controlled study 169
Alterazioni del campo visivo in soggetti epilettici in trattamento cronico con vigabatrin. 167
Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. 165
No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: Use of antiepileptic drugs and dementia risk—An analysis of Finnish health register and German health insurance data 161
A Double-Blind, Placebo-Controlled Study on the Effect of Vigabatrin on In Vivo Parameters of Hepatic Microsomal Enzyme Induction and on the Kinetics of Steroid Oral Contraceptives in Healthy Female Volunteers 160
Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: An in vitro study 157
Basal Ganglia Dysmorphism in Patients With Aicardi Syndrome 154
A PHARMACOLOGICAL AND CLINICAL REVIEW ON TOPIRAMATE, A NEW ANTIEPILEPTIC DRUG, 153
Clinical pharmacokinetics of fluvoxamine. 151
Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (Oxford) 51, 1069-1077, 2010 148
A Prospective study on the effects of antiepileptic drugs on the human foetus: The European Registry initiative 147
Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. 147
Increased Apparent Oral Clearance of Valproic Acid during Intake of Combined Contraceptive Steroids in Women with Epilepsy 143
Low risk pragmatic trials do not always require participants' informed consent 143
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine sources of variability and preliminary observations on relations with clinical response. 141
Enantioselective effects of levodropropizine and dropropizine on psychomotor functions in normal volunteers: a placebo-controlled, double-blind comparative study. 141
Drug interactions with nimesulide. 141
Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. on behalf of the SOPHIE Study Group. 140
A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy 140
Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. 138
Novel Medications for Epilepsy 136
Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. 136
Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. 135
A web-based algorithm to rapidly classify seizures for the purpose of drug selection 135
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. 133
Omeprazole Does Not Enhance the Metabolism of Phenacetin, a Marker of CYP1A2 Activity, in Healthy Volunteers 133
Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe 133
Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age 131
Determination of Perampanel in Dried Plasma Spots: Applicability to Therapeutic Drug Monitoring 131
Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. 130
A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. 129
Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. 128
Antiepileptic drug use and epileptic seizures in nursing home residents in the Province of Pavia, Italy: A reappraisal 12 years after a first survey 128
A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Commentary. 127
2017 International League Against Epilepsy classifications of seizures and epilepsy are steps in the right direction 127
Reversible Pseudoatrophy of the Brain and Mental Deterioration Associated with Valproate Treatment 126
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction 125
Concentrations of L-dopa in plasma and plasma ultrafiltrates. 125
Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience 124
Effects of phenytoin on the in vivo kinetics of thiamine and its phosphoesters in rat nervous tissues 124
Does screening for adverse effects improve health outcomes in epilepsy? A randomized trial 123
Clinically important drug interactions in epilepsy: Interactions between antiepileptic drugs and other drugs. 123
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. 122
Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. 122
Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments.SOPHIE Study Group. 122
The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction 121
Influence of aging on serum phenytoin concentrations: A pharmacokinetic analysis based on therapeutic drug monitoring data. 121
The new antiepileptic drugs: Pharmacological and clinical aspects. 120
Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug perampanel in human plasma 120
Daytime sleepiness in healthy university students: A multiparametric study 119
Pharmacokinetic variability of new antiepileptic drugs at different ages. 118
A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy 118
THE INFLUENCE OF OLD AGE AND ENZYME INDUCING COMEDICATION ON THE PHARMACOKINETICS OF VALPROIC ACID AT STEADY STATE: A CASE-MATCHED EVALUATION BASED ON THERAPEUTIC DRUG MONITORING DATA. 118
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. 117
Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. 116
Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects 115
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). 115
DIFFERENTIAL-EFFECTS OF VALPROIC ACID AND ENZYME-INDUCING ANTICONVULSANTS ON NIMODIPINE PHARMACOKINETICS IN EPILEPTIC PATIENTS 115
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. 115
Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects 114
Comparative pharmacokinetics and pharmacodynamics of eterobarbital and phenobarbital in normal volunteers. 114
Phenobarbital pharmacokinetics in old age: A case-matched evaluation based on therapeutic drug monitoring data. 112
Epilessia nell'anziano:dati dai registri di un centro neurologico. 112
Can drug resistance in epilepsy be minimized? Challenging commonly held beliefs. 112
Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative survey. 112
Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. 111
Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation 111
Seizure control and treatment in pregnancy. Observations from the EURAP Epilepsy Pregnancy Registry 111
Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes 111
Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: a open, prospective, long-term study 110
Plasma gabapentin concentrations in children with epilepsy: Influence of age, relationship with dosage, and preliminary observations on correlation with clinical response 110
Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. 110
Cenobamate: A Review of its Pharmacological Properties, Clinical Efficacy and Tolerability Profile in the Treatment of Epilepsy 110
Role of valproate across the ages. Treatment of epilepsy in the elderly 109
Withdrawing antiepileptic drugs in seizure-free patients: what are the cognitive benefits? 109
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. 109
Overtreatment in epilepsy : How it occurs and how it can be avoided 109
What clinical trial designs have been used to test antiepileptic drugs and do we need to change them? 109
Topiramate pharmacokinetics in children and adults with epilepsy: A case-matched comparison based on therapeutic drug monitoring data. 109
The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? 109
Adverse drug interactions in epilepsy 109
Valproic acid after five decades of use in epilepsy: Time to reconsider the indications of a time-honoured drug 109
A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy 109
CYP2D6-related oxidation polymorphism in Italy 109
Overtreatment in epilepsy: adverse consequences and mechanisms. 108
Vigabatrin and epilepsy. Lessons learned. 108
The Influence of Dosage, Age, and Comedication on Steady State Plasma Lamotrigine Concentrations in Epileptic Children 108
Totale 14.040
Salva come PNG Salva come JPEG
Categoria #
all - tutte 175.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 175.573
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.511 0 0 0 0 20 36 27 101 100 18 275 934
2022/20235.273 641 314 37 471 518 593 0 355 2.110 25 136 73
2023/20241.577 222 281 58 137 170 413 30 107 11 45 60 43
2024/20254.438 141 480 126 178 74 186 145 366 978 166 477 1.121
2025/202611.669 786 1.085 1.420 1.059 1.177 460 2.312 467 873 833 759 438
2026/20275.779 882 1.168 1.197 1.770 762 0 0 0 0 0 0 0
Totale 40.458